Kurse werden geladen...
Prognose
Kaufen |
1 |
Halten |
0
|
Verkaufen |
0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
- 31.07. - 13:21 Uhr
Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Fragile X Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Fragile X Syndrome - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fragile X Syndrome pipeline landscape is provided which includes the disease overview and Fragile X Syndrome treatment guidelines. » Mehr auf globenewswire.com
- 13.10. - 16:52 Uhr
Why Shares of Harmony Bioscience Are Falling on Friday
Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter revenue was up 25%, year over year. » Mehr auf fool.com
- 11.10. - 12:00 Uhr
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa. , Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE). » Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | Juni 2023 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | - |
Nettoeinkommen | 9,87 Mio | - |
EBITDA | 10,07 Mio | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 64,12 Mio € |
Anzahl Aktien | 53,94 Mio |
52 Wochen-Hoch/Tief | 1,28 € - 0,23 € |
Dividenden | Nein |
Beta | 1,19 |
KGV (PE Ratio) | 1,76 |
KGWV (PEG Ratio) | 0,36 |
KBV (PB Ratio) | 2,25 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Zynerba Pharmaceuticals, Inc. ist ein Spezialpharmaunternehmen in der klinischen Phase. Das Unternehmen konzentriert sich auf die Entwicklung pharmazeutisch hergestellter transdermaler Cannabinoid-Therapien für seltene und nahezu seltene neuropsychiatrische Störungen. Es entwickelt Zygel, ein pharmazeutisch hergestelltes Cannabidiol, das als permeationsverbessertes Gel zur transdermalen Verabreichung formuliert ist. Das Unternehmen war früher als AllTranz, Inc. bekannt und änderte im August 2014 seinen Namen in Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Devon, Pennsylvania.
Name | Zynerba Pharmaceuticals |
CEO | Armando Anido MBA |
Sitz | Devon,
pa USA |
Website | |
Industrie | Chemikalien |
Börsengang | 05.08.2015 |
Mitarbeiter | 25 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ZYNE |
Assets entdecken
Shareholder von Zynerba Pharmaceuticals investieren auch in folgende Assets